4D Molecular Therapeutics (FDMT) announced that it has finished enrolling patients for its 4FRONT‑1 Phase 3 study of 4D‑150 in wet age‑related macular degeneration (AMD). The randomized, double‑masked, aflibercept‑controlled trial enrolled 11 months of patients and is now fully enrolled across North America, positioning the company to begin the next phase of the program and to generate topline data in the first half of 2027.
4D‑150 is a single intravitreal injection designed to deliver multi‑year sustained anti‑VEGF therapy, combining aflibercept with anti‑VEGF‑C activity. The candidate has received regulatory‑matters‑advanced‑therapy (RMAT) designation for both wet AMD and diabetic macular edema (DME), underscoring its potential to reduce the treatment burden for millions of patients and to capture a share of the estimated $17 billion annual market for retinal vascular diseases.
The 4FRONT‑2 Phase 3 trial, which is global and includes treatment‑experienced patients, is expected to complete enrollment in the second half of 2026 and to report topline results in the second half of 2027. The parallel development of 4D‑150 for DME and the ongoing 4FRONT‑2 program reinforce FDMT’s strategy of building a portfolio of foundation therapies for retinal diseases.
FDMT’s cash position stands at approximately $505–$506 million, a figure that is expected to fund operations through 2028. Earlier guidance had projected $551 million in cash, sufficient through the first half of 2027, highlighting a slight tightening of the runway but still providing a comfortable buffer for the company’s clinical and regulatory milestones. The company’s partnership with Otsuka Pharmaceutical for the Asia‑Pacific commercialization of 4D‑150 further strengthens its go‑to‑market strategy.
CEO David Kirn emphasized that the 11‑month enrollment period was a “landmark moment” that reflected strong investigator and patient enthusiasm for 4D‑150 as a backbone therapy. Dr. Arshad M. Khanani noted that the rapid enrollment “is particularly encouraging” and signals that the drug’s safety and efficacy profile is resonating with clinicians and patients alike. Together, the milestone and the company’s financial footing suggest that FDMT is well positioned to advance 4D‑150 toward regulatory submission and eventual commercialization while maintaining momentum in its second lead asset, 4D‑710, a gene therapy for cystic fibrosis delivered via aerosol.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.